Key facts
- This page summarizes Alexander C. Reynolds's Form 4 filing for Evelo Biosciences, Inc..
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 12 Jul 2023, 16:08.
Alexander C. Reynolds - 11 Jul 2023 Form 4 Insider Report for Evelo Biosciences, Inc.
- Reporting relationship
- Director
- Issuer ticker
- N/A
- Reported as of
- 11 Jul 2023
- Net transaction value
- $0
- Reporting owner signature
- /s/ Marella Thorell, Attorney-in-Fact for Alexander C. Reynolds
Source evidence
Original filing metadata and source links for verification.
3 source fields
Reporting owner
1 detail
Key filing fact
Alexander C. Reynolds filed Form 4 for Evelo Biosciences, Inc. on 12 Jul 2023.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
EVLO
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +2,000
- Change %
- Price
- $0.000000
- Shares after
- 2,000
- Date
- 11 Jul 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 2,000
- Exercise price
- $3.38
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
The option vests in 36 substantially equal monthly installments following the grant date and has a term of 10 years.
SEC remarks
On June 29, 2023, the Issuer effected a 1-for-20 reverse stock split. The share counts herein have been adjusted to reflect the reverse stock split.